CNBC Reputable source

Samsung Biologics bids $1.8 billion in cash for Switzerland's PolyPeptide Group

Overall sentiment: Neutral

Open original · Jenny Lee

Published Jul 20, 2026 · Retrieved Jul 20, 2026

business science health technology
  1. Samsung Biologics offers 1.46 billion Swiss francs ($1.8 billion) to acquire PolyPeptide Group Newsworthy Reliable Neutral
  2. PolyPeptide shareholders will receive 44.31 Swiss francs per share under the public tender offer Newsworthy Reliable Neutral
  3. The acquisition is expected to close by the end of 2026, marking Switzerland's largest biopharmaceutical M&A Newsworthy Reliable Neutral
  4. Samsung Biologics aims to expand into peptide therapeutics, driven by rising demand for obesity treatments Newsworthy Reliable Positive
  5. PolyPeptide Group specializes in peptide-based active pharmaceutical ingredients and therapeutic peptides Relevant Reliable Neutral
  6. Peptide therapeutics include GLP-1 drugs that mimic hormones to reduce appetite and regulate blood sugar Relevant Reliable Positive
  7. Samsung Biologics will broaden its offerings from antibody drugs to peptide-based GLP-1 therapies Relevant Reliable Positive
  8. The deal expands Samsung Biologics' global footprint via PolyPeptide's R&D and manufacturing in five countries Relevant Reliable Positive

Type: standard news · Analysis confidence: 95%

Used in syntheses